Kan Yonemori

Research interests

Publications

• Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

  Journal of Clinical Oncology · 2024 · 10.1200/jco.2024.42.17_suppl.lba1000

• Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

  New England Journal of Medicine · 2024 · 10.1056/nejmoa2313811

• Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407086

• Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

  Nature Medicine · 2024 · 10.1038/s41591-024-03021-7

• Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

  Journal of Clinical Oncology · 2023 · 10.1200/jco.23.00882

• Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02321-8

• Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

  Journal of Clinical Oncology · 2023 · 10.1200/jco.22.02558

• Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

  Journal of Clinical Oncology · 2023 · 10.1200/jco.22.02152

• First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

  Clinical Cancer Research · 2021 · 10.1158/1078-0432.ccr-20-4740

• Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

  The Lancet Oncology · 2021 · 10.1016/s1470-2045(21)00342-9

• Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00216-3

• Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

  Cancer Science · 2019 · https://doi.org/10.1111/cas.13969

• Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer

  ESMO Open · 2017 · https://doi.org/10.1136/esmoopen-2016-000150

• Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30604-6

• Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities

  Modern Pathology · 2017 · 10.1038/modpathol.2017.11

• Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

  Cancer Science · 2016 · 10.1111/cas.12932

• 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients

  EJNMMI Research · 2015 · 10.1186/s13550-015-0082-6

• 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

  Journal of Nuclear Medicine · 2013 · 10.2967/jnumed.112.118612

• Efficacy of everolimus, a novel m TOR inhibitor, against basal‐like triple‐negative breast cancer cells

  Cancer Science · 2012 · 10.1111/j.1349-7006.2012.02359.x

• Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer

  International Journal of Clinical Oncology · 2011 · https://doi.org/10.1007/s10147-011-0352-x

• Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

  Breast Cancer Research and Treatment · 2011 · 10.1007/s10549-011-1554-7

• FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

  Annals of Oncology · 2010 · 10.1093/annonc/mdq585

• Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer

  British Journal of Cancer · 2009 · 10.1038/sj.bjc.6605360

• Disruption of the blood brain barrier by brain metastases of triple‐negative and basal‐type breast cancer but not HER2/neu‐positive breast cancer

  Cancer · 2009 · 10.1002/cncr.24735

• Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors

  Journal of Neuro-Oncology · 2008 · 10.1007/s11060-008-9758-3

Current projects

No projects listed.